Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 plus platinum-based chemotherapy vs placebo plus chemotherapy in advanced squamous NSCLC
CTR20201294Phase 3Completed
- Sponsor
- Kanion Pharmaceutical
- Start
- Jul 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of erfonrilimab in Pulmonary squamous cell carcinoma, sponsored by Kanion Pharmaceutical. Started Jul 2020; status: completed.
02
Drugs
erfonrilimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20201294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201294.